AI Article Synopsis
- HPV types 16 and 18 are responsible for 70% of cervical cancer cases worldwide, and the nonavalent HPV vaccine (9vHPV) provides protection against additional cancer-causing types.
- Phase III clinical studies show that 9vHPV has over 90% efficacy in preventing cervical, vulvar, and vaginal precancers and its effectiveness is expected to persist for at least five years.
- The implementation of 9vHPV could potentially prevent up to 93% of cervical cancer cases and significantly reduce other HPV-related anogenital cancers globally.
Article Abstract
Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated high vaccine efficacy (>90%) against cervical, vulvar, and vaginal precancers caused by these additional types, and have shown comparable immunogenicity to the shared genotypes to quadrivalent HPV vaccine (4vHPV). Vaccine efficacy and antibody responses for 9vHPV are found to persist for at least five years while longer-term observational studies are ongoing to monitor long-term vaccine effectiveness. The implementation of 9vHPV has the potential to prevent up to 93% of cervical cancer cases, as well as a significant proportion of other HPV-related anogenital cancers. This review article summarizes the current evidence for 9vHPV in terms of vaccine efficacy against HPV infection and related anogenital precancers, safety, and immunogenicity, as well as discussing the potential impact of this vaccine on the cervical cancer burden globally.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613616 | PMC |
| http://dx.doi.org/10.2147/IDR.S178381 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Topical Treatment of Low-Risk Cervical Preinvasive Lesions with Glycyrrhizinic Acid.
J Clin Med
December 2024
Gynaecology Clinic, Riga East Clinical University Hospital, Hipokrata Street 2, LV 1079 Riga, Latvia.
: The study aimed to investigate the efficacy of medication treatment with glycyrrhizinic acid for cervical intraepithelial neoplasia (CIN) 1 lesions. : Women with histologically confirmed CIN 1 in cervical biopsies were included in the prospective study. Participants of the study group used glycyrrhizinic acid spray (Epigen spray) topically 10 days (Epigen 10-day subgroup) or 20 days (Epigen 20-day subgroup) per month for 6 months.
View Article and Find Full Text PDFAgreement Between High-Risk Human Papillomavirus Testing in Paired Self-Collected and Clinician-Collected Samples from Cervical Cancer Screening in Spain.
Cancers (Basel)
December 2024
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
: Implementing self-sampling (SS) in cervical cancer screening requires comparable results to clinician-collected samples (CCS). Agreement measures are essential for evaluating HPV test performance. Previous studies on non-paired samples have reported higher viral cycle threshold (Ct) values in SS compared to CCS, affecting sensitivity for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+).
View Article and Find Full Text PDFmiRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.
Cancers (Basel)
December 2024
Laboratorio de Biomedicina Molecular I, Programas de Doctorado en Ciencias en Biotecnología y Maestría en Biomedicina Molecular, Escuela Nacional de Medicina y Homeopatía (ENMyH), Instituto Politécnico Nacional, Mexico City 07320, Mexico.
Prostate pathologies, including chronic prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa), are strongly associated with chronic inflammation, which is a key risk factor and hallmark of these diseases [...
View Article and Find Full Text PDFRoles of Mature Domain Targeting Signals (MTSs) for Protein Translocation and Secretion in .
Int J Mol Sci
December 2024
Institute of Food Technology, Department of Food Science and Technology, BOKU University, 1190 Vienna, Austria.
is a potential bacterial cell factory to develop delivery systems for vaccines and therapeutic proteins. Much progress has been made in applications using engineered against, e.g.
View Article and Find Full Text PDFTranscriptomic Analysis of HPV-Positive Oesophageal Tissue Reveals Upregulation of Genes Linked to Cell Cycle and DNA Replication.
Int J Mol Sci
December 2024
School of Life Sciences, Pharmacy and Chemistry, Kingston University London, London KT1 2EE, UK.
Human papillomavirus (HPV) is a prevalent sexually transmitted infection, implicated in various cancers, yet its influence in non-cancerous oesophageal tissue remains unclear. This study aims to investigate the gene expression changes associated with high-risk HPV (HR-HPV) in non-cancerous oesophageal tissue to elucidate potential early oncogenic mechanisms. Using RNA sequencing, we compared transcriptomic profiles of HPV-positive and HPV-negative non-cancerous oesophageal tissues.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!